Affordable Access

Inhibition of F1-ATPase from Trypanosoma brucei by its regulatory protein inhibitor TbIF1.

Authors
  • Gahura, Ondřej
  • Panicucci, Brian
  • Váchová, Hana
  • Walker, John E
  • Zíková, Alena
Publication Date
Dec 01, 2018
Source
Apollo - University of Cambridge Repository
Keywords
Language
English
License
Unknown
External links

Abstract

Hydrolysis of ATP by the mitochondrial F-ATPase is inhibited by a protein called IF1 . In the parasitic flagellate, Trypanosoma brucei, this protein, known as TbIF1 , is expressed exclusively in the procyclic stage, where the F-ATPase is synthesizing ATP. In the bloodstream stage, where TbIF1 is absent, the F-ATPase hydrolyzes ATP made by glycolysis and compensates for the absence of a proton pumping respiratory chain by translocating protons into the intermembrane space, thereby maintaining the essential mitochondrial membrane potential. We have defined regions and amino acid residues of TbIF1 that are required for its inhibitory activity by analyzing the binding of several modified recombinant inhibitors to F1 -ATPase isolated from the procyclic stage of T. brucei. Kinetic measurements revealed that the C-terminal portion of TbIF1 facilitates homodimerization, but it is not required for the inhibitory activity, similar to the bovine and yeast orthologs. However, in contrast to bovine IF1 , the inhibitory capacity of the C-terminally truncated TbIF1 diminishes with decreasing pH, similar to full length TbIF1 . This effect does not involve the dimerization of active dimers to form inactive tetramers. Over a wide pH range, the full length and C-terminally truncated TbIF1 form dimers and monomers, respectively. TbIF1 has no effect on bovine F1 -ATPase, and this difference in the mechanism of regulation of the F-ATPase between the host and the parasite could be exploited in the design of drugs to combat human and animal African trypanosomiases. / This work was supported by the Ministry of Education ERC CZ grant LL1205 and Grant Agency of the Czech Republic (18‐17529S) (both to AZ), by European Regional Development Fund (No. CZ.02.1.01/0.0/0.0/16_019/0000759), and by the Medical Research Council of the United Kingdom by Grant 21 522 MC_U1065663150 and by Programme Grant MR/M009858/1 (both to JEW).

Report this publication

Statistics

Seen <100 times